Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Hims & Hers Health, Inc. regarding possible violations of federal securities laws, particularly related to alleged misrepresentations and omissions by the company and its executives [1][2] Group 1: Legal and Regulatory Issues - Novo Nordisk terminated its collaboration with Hims & Hers Health due to serious concerns over the company's sale of compounded medications marketed as personalized treatments, alleging that Hims may have violated regulations by mass-distributing semaglutide-based drugs that could contain unauthorized foreign substances [3] Group 2: Investor Information - Investors who purchased Hims & Hers securities and incurred significant losses may be eligible to participate in a potential class action to recover their losses [2]

Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential securities claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and regulatory compliance issues [1][3][4] Company Overview - Hims & Hers is a telehealth company based in San Francisco, California, providing prescription treatments for various health issues, including weight loss, sexual health, mental health, and dermatology [2] - The company has recently entered the GLP-1 medication market, which includes drugs for obesity and type 2 diabetes, specifically semaglutide, the active ingredient in Novo Nordisk's Wegovy® and Ozempic® [2] Recent Developments - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing deceptive marketing practices and the sale of unapproved compounded versions of semaglutide [3] - Following this announcement, Hims & Hers shares fell by over 26% during intraday trading, indicating significant investor concern regarding the company's regulatory compliance and reputational risks [3] Investigation Details - Berger Montague is investigating whether Hims & Hers and its officers made materially false or misleading statements or omitted important information about the regulatory status of its GLP-1 offerings and the risks associated with its partnership with Novo Nordisk [4]

Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and safety risks associated with its products [1][3]. Group 1: Investigation Details - Kirby McInerney LLP is investigating claims against Hims & Hers regarding possible violations of federal securities laws and other unlawful business practices [1]. - The investigation is prompted by allegations that Hims & Hers engaged in deceptive marketing and sold illegitimate versions of Novo Nordisk's weight loss drug Wegovy [3]. Group 2: Partnership and Market Impact - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk to sell Wegovy [3]. - The partnership was terminated on June 23, 2025, leading to a significant decline in Hims & Hers' stock price, which fell approximately 34% from $64.22 to $41.97 per share [3].

Company Performance & Core Business - Hims & Hers stock experienced a 30% crash following accusations of deceptive marketing by Novo Nordisk [1] - The company's core business has been heavily reliant on erectile dysfunction and baldness drugs [3][4] - Weight loss drugs, specifically compounded medications, now constitute over 50% of Hims & Hers' business [6] - The core business, excluding weight loss drugs, is reportedly declining or decelerating [7] Regulatory & Competitive Risks - Hims & Hers is operating in a "gray area" by compounding patented weight loss drugs, leading to concerns from Novo Nordisk [6] - The company's reliance on compounded weight loss drugs poses a significant risk if regulatory changes occur [6] - Alternative options for obtaining ED drugs exist, potentially undercutting Hims & Hers' market share [5] Market Sentiment & Investor Perspective - The stock was previously flagged as a "smug and senseless" investment, driven by speculative buying [3] - The stock had doubled since May 2024, but the underlying risks remain unchanged [3] - The negative news from Novo Nordisk came as an "out of left field surprise," even after a recent collaborative deal [8]

Core Viewpoint - Hims & Hers Health Inc experienced a significant stock decline of 34% following the termination of its relationship with Novo Nordisk, raising questions about the future of the company amidst regulatory challenges and market dynamics [1]. Company Overview - Hims & Hers is a high-growth telehealth firm that provides a range of health products, including hair loss medications and mental health prescriptions [1]. - The company generated approximately $200–225 million in 2024 from its GLP-1 business, which constituted a substantial portion of its projected $1.48 billion revenue [4]. Regulatory Challenges - The FDA's recent declaration that supply shortages are resolved has rendered compounded GLP-1 alternatives illegal, leading to accusations from Novo Nordisk against Hims for ignoring regulatory compliance [2]. - Novo Nordisk's actions signal a broader regulatory scrutiny within the telehealth industry, indicating potential challenges for companies operating in this space [4]. Financial Metrics - Hims is currently trading at a forward P/E ratio of 69.4, which is over 2.5 times the sector median, and a PEG ratio of 3.9, suggesting that the current valuation may be difficult to justify without significant earnings growth [3]. - The stock has seen a year-to-date decline of 66% and is trading below its eight, 20, and 50-day moving averages, with an RSI of 38.69, indicating it is nearing oversold conditions [6]. Market Position and Future Outlook - Despite the challenges, over 80% of Hims' revenue is derived from non-weight-loss verticals, such as acne and anxiety treatments, which are expected to remain stable [5]. - The company is recognized as a leading direct-to-consumer health brand among millennials and Gen Z, which may provide a foundation for future growth [5]. - The MACD indicator is currently positive at 0.48, suggesting a potential bullish signal, while the stock remains above the 200-day moving average, indicating some long-term trend support [7].

Core Insights - Novo Nordisk announced the discontinuation of its partnership with Hims & Hers, leading to a ~30% drop in Hims' stock price in one day [1] Company Overview - Hims & Hers is a publicly traded company on NYSE under the ticker HIMS [1] - The company focuses on health and wellness products, particularly in telehealth services [1] Market Reaction - The announcement from Novo Nordisk resulted in a significant market reaction, with Hims' stock falling approximately 30% [1] Analyst Background - MMMT Wealth, managed by Oliver, focuses on investment strategies and stock analysis, particularly in private equity, hedge funds, and asset management [1] - Oliver has 5 years of investing experience and 4 years as a CPA, emphasizing thorough research on businesses [1]

Hims & Hers Health TodayHIMSHims & Hers Health$42.09 -22.13 (-34.46%) 52-Week Range$13.47▼$72.98P/E Ratio61.00Price Target$38.00Add to WatchlistIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years. Still, today, there is one name that possesses all the right components (and timing) to make it a suitable investment for those seeking to compound their wealth in the coming years. This company is popular among value investors and in the retail ...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Why is Hims & Hers being Investigated? Hims & Hers is a telehealth company that provides consumers access to ...

Core Viewpoint - Novo Nordisk terminated its collaboration with Hims & Hers due to legal and safety concerns regarding the marketing and sale of compounded drugs, particularly Wegovy [4][5]. Group 1: Termination of Collaboration - Novo Nordisk announced the end of its partnership with Hims & Hers, stating that the latter failed to comply with legal standards and engaged in deceptive marketing practices [4][5]. - The collaboration was short-lived, lasting just over a month, and was marked by public disputes over marketing strategies [5][10]. Group 2: Impact on Hims & Hers - Following the announcement, Hims & Hers' stock plummeted nearly 35%, indicating significant investor concern over the loss of access to Wegovy [8][10]. - Hims & Hers had previously identified achieving a leadership position in the weight-loss market as a top priority, with the integration of Wegovy through NovoCare being a key strategy [9]. - The company will now only be able to offer a personalized compounded version of Wegovy, which limits its ability to provide this popular weight-loss drug [10]. Group 3: Impact on Novo Nordisk - Novo Nordisk's share price fell approximately 5% following the termination of the deal, reflecting a more muted impact compared to Hims & Hers [11]. - The company plans to continue working with other telehealth platforms to provide access to Wegovy while ensuring patient safety [12].

Core Insights - Hims & Hers Health experienced a 35% stock crash following the termination of its partnership with Novo Nordisk, raising concerns about its long-term viability in the weight-loss drug market [2][3][11] - The partnership, which began in April 2025, was expected to provide access to Novo Nordisk's Wegovy, significantly contributing to HIMS's stock surge of 150% earlier in the year [3][4] Partnership Details - The collaboration was short-lived, lasting only two months, as Novo Nordisk cited HIMS's "illegal mass compounding and deceptive marketing" practices as reasons for the termination [4][5] - HIMS's continued sales of personalized compounded versions of semaglutide conflicted with the partnership's goals, leading to a fundamental tension in the weight-loss drug market [5][6] Valuation and Market Reaction - Following the stock crash, HIMS trades at approximately seven times trailing revenues, more than double its five-year historical average of three times revenues [7][8] - If HIMS were to revert to its historical valuation multiple, the stock could fall to around $25, indicating a potential further decline of 40% from current levels [8] Future Outlook - HIMS can continue selling personalized obesity treatments, but faces regulatory uncertainties and the loss of a significant revenue stream from Wegovy [9][10] - The company's remaining business model may not generate sufficient growth to justify its current premium valuation, as the personalized approach is unlikely to match the scale of direct Wegovy sales [10][11] Investment Considerations - The situation represents a shift in the investment thesis, suggesting that investors should be cautious and avoid "buying the dip" due to the altered growth prospects and increased regulatory risks [11][12] - The market's reaction indicates that the loss of a primary growth catalyst can lead to significant declines, and future growth pathways for HIMS are uncertain and likely less lucrative [12]